492 related articles for article (PubMed ID: 25645594)
21. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.
Goyal NA; Mozaffar T
Expert Opin Investig Drugs; 2014 Nov; 23(11):1541-51. PubMed ID: 24965719
[TBL] [Abstract][Full Text] [Related]
22. Stem-cell therapy for amyotrophic lateral sclerosis.
Silani V; Cova L; Corbo M; Ciammola A; Polli E
Lancet; 2004 Jul 10-16; 364(9429):200-2. PubMed ID: 15246734
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of stem cell therapies in amyotrophic lateral sclerosis.
Srivastava AK
Neurol India; 2014; 62(3):239-48. PubMed ID: 25033844
[TBL] [Abstract][Full Text] [Related]
24. Toward the treatments with neural stem cells: experiences from amyotrophic lateral sclerosis.
Mitrecić D; Gajović S; Pochet R
Anat Rec (Hoboken); 2009 Dec; 292(12):1962-7. PubMed ID: 19943351
[TBL] [Abstract][Full Text] [Related]
25. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future.
Lunn JS; Sakowski SA; Feldman EL
Stem Cells; 2014 May; 32(5):1099-109. PubMed ID: 24448926
[TBL] [Abstract][Full Text] [Related]
26. Advances, Challenges, and Perspectives in Translational Stem Cell Therapy for Amyotrophic Lateral Sclerosis.
Abati E; Bresolin N; Comi G; Corti S
Mol Neurobiol; 2019 Oct; 56(10):6703-6715. PubMed ID: 30911936
[TBL] [Abstract][Full Text] [Related]
27. Neural Stem Cells and Human Induced Pluripotent Stem Cells to Model Rare CNS Diseases.
De Filippis L; Zalfa C; Ferrari D
CNS Neurol Disord Drug Targets; 2017; 16(8):915-926. PubMed ID: 28641519
[TBL] [Abstract][Full Text] [Related]
28. Overview of stem cells therapy in amyotrophic lateral sclerosis.
Je G; Keyhanian K; Ghasemi M
Neurol Res; 2021 Aug; 43(8):616-632. PubMed ID: 33632084
[No Abstract] [Full Text] [Related]
29. Induced pluripotent stem cells in modeling and cell-based therapy of amyotrophic lateral sclerosis.
Csobonyeiova M; Polak S; Nicodemou A; Danisovic L
J Physiol Pharmacol; 2017 Oct; 68(5):649-657. PubMed ID: 29375039
[TBL] [Abstract][Full Text] [Related]
30. Neural and glial progenitor transplantation as a neuroprotective strategy for Amyotrophic Lateral Sclerosis (ALS).
Haidet-Phillips AM; Maragakis NJ
Brain Res; 2015 Dec; 1628(Pt B):343-350. PubMed ID: 26187754
[TBL] [Abstract][Full Text] [Related]
31. Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis.
Ciervo Y; Ning K; Jun X; Shaw PJ; Mead RJ
Mol Neurodegener; 2017 Nov; 12(1):85. PubMed ID: 29132389
[TBL] [Abstract][Full Text] [Related]
32. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials.
Goutman SA; Savelieff MG; Sakowski SA; Feldman EL
Expert Opin Investig Drugs; 2019 Jun; 28(6):525-543. PubMed ID: 31189354
[TBL] [Abstract][Full Text] [Related]
33. Mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis: signals for hope?
Allers C; Jones JA; Lasala GP; Minguell JJ
Regen Med; 2014; 9(5):637-47. PubMed ID: 25372079
[TBL] [Abstract][Full Text] [Related]
34. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes.
Feldman EL; Boulis NM; Hur J; Johe K; Rutkove SB; Federici T; Polak M; Bordeau J; Sakowski SA; Glass JD
Ann Neurol; 2014 Mar; 75(3):363-73. PubMed ID: 24510776
[TBL] [Abstract][Full Text] [Related]
35. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients.
Kwon MS; Noh MY; Oh KW; Cho KA; Kang BY; Kim KS; Kim YS; Kim SH
J Neurochem; 2014 Oct; 131(2):206-18. PubMed ID: 24995608
[TBL] [Abstract][Full Text] [Related]
36. Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets.
Ferraiuolo L; Maragakis NJ
Neurosci Lett; 2021 Jun; 755():135911. PubMed ID: 33892003
[TBL] [Abstract][Full Text] [Related]
37. Drug screening for ALS using patient-specific induced pluripotent stem cells.
Egawa N; Kitaoka S; Tsukita K; Naitoh M; Takahashi K; Yamamoto T; Adachi F; Kondo T; Okita K; Asaka I; Aoi T; Watanabe A; Yamada Y; Morizane A; Takahashi J; Ayaki T; Ito H; Yoshikawa K; Yamawaki S; Suzuki S; Watanabe D; Hioki H; Kaneko T; Makioka K; Okamoto K; Takuma H; Tamaoka A; Hasegawa K; Nonaka T; Hasegawa M; Kawata A; Yoshida M; Nakahata T; Takahashi R; Marchetto MC; Gage FH; Yamanaka S; Inoue H
Sci Transl Med; 2012 Aug; 4(145):145ra104. PubMed ID: 22855461
[TBL] [Abstract][Full Text] [Related]
38. New therapy options for amyotrophic lateral sclerosis.
Gordon P; Corcia P; Meininger V
Expert Opin Pharmacother; 2013 Oct; 14(14):1907-17. PubMed ID: 23855817
[TBL] [Abstract][Full Text] [Related]
39. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
40. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis.
Suzuki M; Svendsen CN
Trends Neurosci; 2008 Apr; 31(4):192-8. PubMed ID: 18329734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
